BIO vs. RGEN: Bio-Rad Laboratories vs. Repligen Stock Comparison
How do Bio-Rad Laboratories (BIO) and Repligen (RGEN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Bio-Rad Laboratories (BIO) and Repligen (RGEN) are both classified in the Life Sciences Tools & Services sub-industry within the broader Life Sciences Tools & Services industry, placing them in the closest GICS peer bucket.
| Profile Item | BIO | RGEN |
|---|---|---|
| Name | Bio-Rad Laboratories Inc. | Repligen Corporation |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| GICS Sub-Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| Market Capitalization | 10.26 billion USD | 11.09 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | February 27, 1980 | April 29, 1986 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | BIO | RGEN |
|---|---|---|
| Total Return (1Y) | 28.31% | 23.28% |
| Total Return (3Y, Annualized) | 8.52% | 6.20% |
| Total Return (5Y, Annualized) | -11.74% | -8.41% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | BIO | RGEN |
|---|---|---|
| Volatility (1Y, Annualized) | 36.50% | 46.73% |
| Beta (5Y) | 1.03 | 1.11 |
| Max Drawdown (5Y) | -72.24% | -64.67% |
| Avg. Volume (3M) | 250.78K | 1.18M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | BIO | RGEN |
|---|---|---|
| Sharpe Ratio (1Y) | 0.66 | 0.41 |
| Sortino Ratio (1Y) | 0.98 | 0.60 |
Profitability
ROE (TTM)
Repligen (RGEN) reports a negative ROE of -0.57%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Bio-Rad Laboratories (BIO) reports 14.27%, ranking against industry peers normally.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
14.27%
- Max
- 109.18%
- BIO
- 14.27%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-0.57%
- Max
- 109.18%
- Q3
- 6.23%
- RGEN
- -0.57%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Repligen (RGEN) reports a negative net margin of -1.47%, usually indicating a net loss over the period. Meanwhile Bio-Rad Laboratories (BIO) reports 39.45%, ranking against industry peers normally.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
39.45%
- BIO
- 39.45%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-1.47%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- RGEN
- -1.47%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Bio-Rad Laboratories (BIO) at 11.82% and Repligen (RGEN) at 6.19% run core operations about as efficiently as their industries’ norm — neither stands out on operating profitability.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
11.82%
- Max
- 83.12%
- Q3
- 14.77%
- BIO
- 11.82%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.19%
- Max
- 83.12%
- Q3
- 14.77%
- RGEN
- 6.19%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | BIO | RGEN |
|---|---|---|
| ROE (TTM) | 14.27% | -0.57% |
| ROA (TTM) | 1.50% | 1.40% |
| Net Margin (TTM) | 39.45% | -1.47% |
| Operating Margin (TTM) | 11.82% | 6.19% |
| Gross Margin (TTM) | 52.19% | 53.77% |
Growth
Revenue Growth
Both Bio-Rad Laboratories (BIO) at 0.65% and Repligen (RGEN) at 16.36% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Neither Bio-Rad Laboratories (BIO) nor Repligen (RGEN) reports a EPS growth value for this period, so a direct comparison isn't possible.
Growth Metrics
| Metric | BIO | RGEN |
|---|---|---|
| Revenue Growth (YoY) | 0.65% | 16.36% |
| Revenue Growth (3Y CAGR) | -2.68% | -2.70% |
| EPS Growth (YoY) | -- | -- |
| EPS Growth (3Y CAGR) | -- | -35.73% |
Financial Strength
Current Ratio (MRQ)
Both Bio-Rad Laboratories (BIO) at 3.18 and Repligen (RGEN) at 9.88 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.18
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- BIO
- 3.18
- Q1
- 2.47
- Min
- 0.10
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
9.88
- Max
- 25.13
- Q3
- 12.13
- RGEN
- 9.88
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Both Bio-Rad Laboratories (BIO) at 0.18 and Repligen (RGEN) at 0.33 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.18
- Max
- 1.42
- Q3
- 0.65
- BIO
- 0.18
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.33
- Max
- 1.42
- Q3
- 0.65
- RGEN
- 0.33
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | BIO | RGEN |
|---|---|---|
| Current Ratio (MRQ) | 3.18 | 9.88 |
| Debt / Equity (MRQ) | 0.18 | 0.33 |
| Net Debt / EBITDA | -0.73 | -1.19 |
Dividends
Dividend Yield (TTM)
Neither Bio-Rad Laboratories (BIO) nor Repligen (RGEN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BIO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- RGEN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Bio-Rad Laboratories (BIO) nor Repligen (RGEN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BIO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- RGEN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | BIO | RGEN |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: Bio-Rad Laboratories (BIO) trades at 10.14 times trailing earnings, ranked against its peers, while Repligen (RGEN) has no P/E ratio this period.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
10.14
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- BIO
- 10.14
- Min
- 0.07
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- RGEN
- --
P/S Ratio (TTM)
On P/S ratio, both Bio-Rad Laboratories (BIO) at 3.96 and Repligen (RGEN) at 13.77 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.96
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- BIO
- 3.96
- Q1
- 3.01
- Min
- 0.01
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.77
- Max
- 58.18
- Q3
- 25.77
- RGEN
- 13.77
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Bio-Rad Laboratories (BIO) at 1.35 sits in the lower P/B ratio quartile against book while Repligen (RGEN) at 4.70 is valued near its industry’s middle — BIO is cheaper on assets, though weigh it against ROE and asset quality.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.35
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- BIO
- 1.35
- Min
- -5.59
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.70
- Max
- 13.53
- Q3
- 6.54
- RGEN
- 4.70
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | BIO | RGEN |
|---|---|---|
| P/E Ratio (TTM) | 10.14 | -- |
| P/S Ratio (TTM) | 3.96 | 13.77 |
| P/B Ratio (MRQ) | 1.35 | 4.70 |
| Free Cash Flow Yield (TTM) | 2.65% | 1.01% |